Antimicrobial activity of a ferrocene-substituted carborane derivative targeting multidrug-resistant infection

Biomaterials

Volumn 34, Issue 4, 2013, Pages 902-911

  Li, Shuihong ^a   Wang, Zhaojin ^b   Wei, Yuanfeng ^c   Wu, Changyu ^a   Gao, Shengping ^a   Jiang, Hui ^a   Zhao, Xinqing ^d   Yan, Hong ^b   Wang, Xuemei ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Antibacterial; Antibiofilm; Ferrocene substituted carborane derivative; Multidrug resistant infection; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

ANTI-BIOFILM; ANTIBACTERIAL; CARBORANE DERIVATIVES; MULTIDRUG-RESISTANT INFECTION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

BACTERICIDES; BACTERIOLOGY; BIOCOMPATIBILITY; BLOOD; IRON COMPOUNDS; ORGANOMETALLICS;

BACTERIA;

CARBORANE DERIVATIVE; FERROCENE SUBSTITUTED CARBORANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HEMOLYSIS; INTERSTITIAL PNEUMONIA; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PHYSIOLOGICAL PHENOMENA; BORANES; CARBON; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FERROUS COMPOUNDS; MALE; MICE; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84870337287     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.069     Document Type: Article

References (30)

1. Spellberg B., Powers J.H., Brass E.P., Miller L.G., Edwards J.E. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004, 38:1279-1286.
2. Huang C.M., Chen C.H., Pornpattananangkul D., Zhang L., Chan M., Hsieh M.F., et al. Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids. Biomaterials 2011, 32:214-221.
3. Høiby N., Bjarnsholt T., Givskov M., Molin S., Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010, 35:322-332.
4. Lewis K. Riddle of biofi{ligature}lm resistance. Antimicrob Agents Chemother 2001, 45:999-1007.
5. Dombrowski K.E., Baldwin W., Sheats J.E. Metallocenes in biochemistry, microbiology & medicine. J Organomet Chem 1986, 302:281-306.
6. van Staveren D.R., Metzler-Nolte N. Bioorganometallic chemistry of ferrocene. Chem Rev 2004, 104:5931-5986.
7. Fouda M.F.R., Abd-Elzaher M.M., Abdelsamaia R.A., Labib A.A. On the medicinal chemistry of ferrocene. Appl Organometal Chem 2007, 21:613-625.
8. Fish R.H., Jaouen G. Bioorganometallic chemistry: structural diversity of organometallic complexes with bioligands and molecular recognition studies of several supramolecular hosts with biomolecules, alkali-metal ions, and organometallic pharmaceuticals. Organometallics 2003, 22:2166-2177.
9. Caldwell1 G., Meirim1 M.G., Neuse1 E.W., van Rensburg C.E.J. Antineoplastic activity of polyaspartamide-ferrocene conjugates. Appl Organometal Chem 1998, 12:793-799.
10. Wu X., Tiekink E.R.T., Kostetski I., Kocherginsky N., Tan A.L.C., Khoo S.B., et al. Antiplasmodial activity of ferrocenyl chalcones: investigations into the role of ferrocene. Eur J Pharm Sci 2006, 27:175-187.
11. Biot C., Daher W., Ndiaye C.M., Melnyk P., Pradines B., Chavain N., et al. Probing the role of the covalent linkage of ferrocene into a chloroquine template. J Med Chem 2006, 49:4707-4714.
12. Biot C., François N., Maciejewski L., Brocard J., Poulain D. Synthesis and antifungal activity of a ferrocene-fluconazole analogue. Bioorg Med Chem Lett 2000, 10:839-841.
13. Chantson J.T., Verga Falzacappa M.V., Crovella S., Metzler-Nolte N. Solid-phase synthesis, characterization, and antibacterial activities of metallocene-peptide bioconjugates. ChemMedChem 2006, 1:1268-1274.
14. Armstrong A.F., Valliant J.F. The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy. Dalton Trans 2007, 38:4240-4251.
15. 10). Organometallics 1999, 18:2738-2740.
16. Barriga S., Marcos C.F., Riant O., Torroba T. Synthesis of poly-ferrocene heterocycles by cycloaddition of mono- or bis(ferrocenecarbonyl)acetylenes and bis[1,2]dithiolo[1,4]thiazinethiones. Tetrahedron 2002, 58:9785-9792.
17. Bruker SMART, version 5.0; SAINT, version 6; SHELXTL, version 6.1; SADABS, version 2.03 2000, Bruker AXS Inc., Madison, WI.
18. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard 2008, Document M7-A8, CLSI, Wayne, PA. 8th ed.
19. Kaplow L.S. Leukocyte alkaline phosphatase cytochemistry: applications and methods. Ann NY Acad Sci 1968, 155:911-947.
20. Lee M.H., Arrecubieta C., Martin F.J., Prince A., Borczuk A.C., Lowy F.D. A postinfl{ligature}uenza model of Staphylococcus aureus pneumonia. J Infect Dis 2010, 201:508-515.
21. Lathem W.W., Crosby S.D., Miller V.L., Goldman W.E. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. P Natl Acad Sci U S A 2005, 102:17786-17791.
22. Keele D.J., DeLallo V.C., Lewis R.E., Ernst E.J., Klepser M.E. Evaluation of amphotericin B and fl{ligature}ucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagn Micr Infec Dis 2001, 41:121-126.
23. Klepser M.E., Malone D., Lewis R.E., Ernst E.J., Pfaller M.A. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000, 44:1917-1920.
24. Pendland S.L., Neuhauser M.M., Prause J.L. In vitro bactericidal activity and post-antibiotic effect of ABT-773 versus co-amoxiclav against anaerobes. J Antimicrob Chemother 2002, 49:879-882.
25. National Committee for Clinical Laboratory Standards Methods for determining bactericidal activity antimicrobial agents; Tentative guideline; NCCLS document M26-T 1992, National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. Wang X.Q., Yao X., Zhu Z.A., Tang T.T., Dai K.R., Sadovskaya I., et al. Effect of berberine on Staphylococcus epidermidis biofi{ligature}lm formation. Int J Antimicrob Agents 2009, 34:60-66.
27. Branda S.S., Vik S., Friedman L., Kolter R. Biofi{ligature}lms: the matrix revisited. Trends Microbiol 2005, 13:20-26.
28. Zhao Y.Y., Tian Y., Cui Y., Liu W.W., Ma W.S., Jiang X.Y. Small molecule-capped gold nanoparticles as potent antibacterial agents that target Gram-negative bacteria. J Am Chem Soc 2010, 132:12349-12356.
29. Fischer D., Li Y.X., Ahlemeyer B., Krieglstein J., Kissel T. In vitro cytotoxicity testing of polycations: infl{ligature}uence of polymer structure on cell viability andhemolysis. Biomaterials 2003, 24:1121-1131.
30. International Standardization Organization Biological evaluation of medical devices. Sample preparation and reference materials 2009, British Standard ISO 10993-12.